Article
Implementation and Audit of Mainstream Genetic Testing Within a High-Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion.
The breast journal - 1 Jan 2026
Conroy Soraya, Keane Emma, Rehman Bushra, Wyborn Eleanor, Brown Catherine, Chen Lamb, Chatten Josh, Durston-Rand Elijah, Sheehan Blaise, Ferguson Elizabeth, Miles Tracie, Beck Emma, Hunter-Smith Alison, Laban Christiana, Smith Katherine, Dalgliesh Diana, Bowen Rebecca, Laurence Nicola
Abstract excerpt
INTRODUCTION: It is estimated that 5%-10% of patients who develop breast cancer have a causative inherited pathogenic or likely pathogenic variant (P/LP variant). In 2020, the UK National Test Directory published criteria for mainstream genetic testing for breast cancer patients (R208) and, subsequently, eligibility criteria to determine which patients are eligible for gene testing and PARP inhibitor treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.